下肢静脉血栓防治的中西医研究进展
Research Progress of Traditional Chinese and Western Medicine in the Prevention and Treatment of Lower Extremity Deep Vein Thrombosis
DOI: 10.12677/tcm.2026.154194, PDF,    科研立项经费支持
作者: 田继东, 钟建春*:甘肃省中医院骨关节病科,甘肃 兰州;刘兆隆, 张龙岗:甘肃中医药大学中医临床学院,甘肃 兰州;张晓菊:甘肃省中医院门诊部,甘肃 兰州;田镕恺:滨州医学院医学影像学院,山东 滨州
关键词: 静脉血栓“脉痹”活血化瘀中西医结合Deep Vein Thrombosis “Maibi” (Vessel Impediment) Promoting Blood Circulation and Removing Blood Stasis Integration of Traditional Chinese and Western Medicine
摘要: 在下肢静脉血栓(DVT)的防治中,中医药展现出独特的临床优势与广阔的应用前景。现代医学视DVT为血流淤滞、血管壁损伤及高凝状态综合作用的结果;中医学则多将其归属“脉痹”、“脉阻”范畴,核心病机为气滞血瘀、湿热壅阻与正虚邪实。临床上,中医药以活血化瘀、益气扶正、祛湿清热及疏通经络为治则,涵盖内服、外治、针灸针刀及中西医结合等多元疗法。现代研究表明,中医药能够通过抗凝、抗炎、抗氧化、改善血液流变及保护内皮等途径,并调控PI3K/Akt、NF-κB等信号通路,发挥多靶点干预作用。针对当前研究存在的临床设计局限、辨证标准不一及机制探讨不深等问题,未来亟待加强高质量循证医学研究与微观机制探索,以推动DVT标准化与精准化防治体系的建设。
Abstract: In the prevention and treatment of lower extremity deep vein thrombosis (DVT), traditional Chinese medicine (TCM) has demonstrated unique clinical advantages and broad application prospects. Modern medicine considers DVT as the result of the combined effects of blood flow stasis, vascular wall injury, and a hypercoagulable state. In contrast, TCM mostly categorizes it under the concepts of “Maibi” (vessel impediment) and “Maizu” (vessel obstruction), with the core pathogenesis being Qi stagnation and blood stasis, damp-heat accumulation, and the coexistence of healthy Qi deficiency and pathogenic excess. Clinically, TCM promotes blood circulation and removes blood stasis, replenishes Qi and strengthens healthy Qi, eliminates dampness and clears heat, and dredges collaterals as its therapeutic principles. It encompasses multiple therapies, including internal administration, external treatment, acupuncture, and needle-knife, as well as the integration of traditional Chinese and Western medicine. Modern research indicates that TCM can exert multi-target intervention effects through pathways such as anticoagulation, anti-inflammation, antioxidation, improving hemorheology, and protecting the endothelium, while also regulating signaling pathways like PI3K/Akt and NF-κB. Addressing current research issues—such as clinical design limitations, inconsistent syndrome differentiation standards, and inadequate mechanism exploration—there is an urgent need to strengthen high-quality evidence-based medical research and microscopic mechanism investigation in the future. This will help promote the construction of a standardized and precise prevention and treatment system for DVT.
文章引用:田继东, 刘兆隆, 钟建春, 张晓菊, 田镕恺, 张龙岗. 下肢静脉血栓防治的中西医研究进展[J]. 中医学, 2026, 15(4): 156-162. https://doi.org/10.12677/tcm.2026.154194

参考文献

[1] 陈泉, 陈跃鑫, 戴向晨, 等. 静脉外科热点问题解析[J]. 中国实用外科杂志, 2022, 42(12): 1321-1342.
[2] 石腾博, 倘艳锋, 张孟瑜, 等. 高剂量低分子量肝素对股骨干骨折愈合的影响[J]. 中国组织工程研究, 2026, 30(12): 2957-2964.
[3] Ma, H., Wang, X., Xue, Q., Li, X., Liang, Z., Heianza, Y., et al. (2023) Cardiovascular Health and Life Expectancy among Adults in the United States. Circulation, 147, 1137-1146. [Google Scholar] [CrossRef] [PubMed]
[4] Li, Z., Zhao, Y., Suguro, S. and Suguro, R. (2023) MicroRNAs Regulate Function in Atherosclerosis and Clinical Implications. Oxidative Medicine and Cellular Longevity, 2023, Article ID: 2561509. [Google Scholar] [CrossRef] [PubMed]
[5] 郝媌, 王洪娟, 马艳华, 等. 基于《内经》“营卫学说”指导下探讨动脉粥样硬化相关慢病认识与防治[J]. 世界中西医结合杂志, 2024, 19(7): 1278-1283.
[6] 冯宇. 《医林改错》中活血化瘀法3层分类探析[J]. 湖北中医杂志, 2023, 45(12): 47-50.
[7] 蔡明, 蔡静雯, 张蜜, 等. 经典名方桃红四物汤化学成分、药理作用和临床应用的研究进展及质量标志物的预测分析[J]. 中国中药杂志, 2025, 50(20): 5671-5683.
[8] 张奎明, 葛鸾蝶, 张林悦, 等. 基于p38MAPK信号通路探讨中医药防治脑缺血再灌注损伤[J]. 广州中医药大学学报, 2022, 39(6): 1417-1422.
[9] Zhong, L., Zhuang, J., Jin, Z., Chen, Y. and Chen, B. (2020) Effect of Chinese Medicine for Promoting Blood Circulation on Microvascular Angina: A Systematic Review and Meta-Analysis. The American Journal of Emergency Medicine, 38, 2681-2692. [Google Scholar] [CrossRef] [PubMed]
[10] 徐帅, 张玲, 赵玉清, 等. 中药多靶点干预代谢综合征血管内皮损伤研究进展[J]. 中国药物警戒, 2023, 20(3): 353-359.
[11] 张军, 张玥, 刘效敏, 等. 针灸疗法预防深静脉血栓形成的临床研究进展[J]. 中国中西医结合外科杂志, 2022, 28(6): 920-924.
[12] 李纪新, 周瑞玲, 黄弘博, 等. 中药及活性成分干预动脉粥样硬化的关键途径: 血管平滑肌细胞增殖、迁移与表型转化[J]. 中国中药杂志, 2025, 50(23): 6583-6597.
[13] 黄彭, 孟祥奇, 吴晨熙, 等. 中医药预防骨科大手术后深静脉血栓形成的研究进展[J]. 中国中医急症, 2020, 29(11): 2062-2065+2068.
[14] 吴梦玮. 中医临床适宜技术在治未病中心的应用[J]. 中国医药科学, 2020, 10(15): 65-70+81.
[15] Maaliki, D., Shaito, A.A., Pintus, G., El-Yazbi, A. and Eid, A.H. (2019) Flavonoids in Hypertension: A Brief Review of the Underlying Mechanisms. Current Opinion in Pharmacology, 45, 57-65. [Google Scholar] [CrossRef] [PubMed]
[16] Ge, B., Zhang, Z. and Zuo, Z. (2014) Updates on the Clinical Evidenced Herb‐Warfarin Interactions. Evidence-Based Complementary and Alternative Medicine, 2014, Article ID: 957362. [Google Scholar] [CrossRef] [PubMed]
[17] Tan, C.S.S. and Lee, S.W.H. (2020) Warfarin and Food, Herbal or Dietary Supplement Interactions: A Systematic Review. British Journal of Clinical Pharmacology, 87, 352-374. [Google Scholar] [CrossRef] [PubMed]
[18] 孔雪云, 陈琦, 吴祥, 等. 中西药联用相互作用研究进展[J]. 南京中医药大学学报, 2018, 34(1): 5-11.
[19] 殷硕, 于月, 郭兴蕾, 刘高峰. 中药对华法林作用的影响及机制概述[J]. 中国临床药理学与治疗学, 2015, 20(3): 327-334.
[20] 王佐梅, 肖洪彬, 牛雯颖, 等. 常见活血化瘀药对血小板的影响作用[J]. 中华中医药学刊, 2021, 39(2): 78-81.
[21] Xu, S., Jin, T. and Weng, J. (2022) Endothelial Cells as a Key Cell Type for Innate Immunity: A Focused Review on RIG-I Signaling Pathway. Frontiers in Immunology, 13, Article ID: 951614. [Google Scholar] [CrossRef] [PubMed]
[22] 赵珺. 下肢慢性静脉疾病的药物治疗[J]. 中国实用外科杂志, 2023, 43(12): 1358-1364.
[23] Khodadi, E. (2019) Platelet Function in Cardiovascular Disease: Activation of Molecules and Activation by Molecules. Cardiovascular Toxicology, 20, 1-10. [Google Scholar] [CrossRef] [PubMed]
[24] 陈旺, 谯茹, 贺鹏, 等. 基于因子旋转法与超分子“印迹模板”的活血化瘀中药“物质单元”解析[J]. 中草药, 2025, 56(17): 6159-6172.
[25] 何洁, 胡建新. 基于Apriori算法的中药注射液治疗血瘀证用药规律分析[J]. 临床合理用药, 2025, 18(4): 7-12.